Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 12-Week play program boost development in At-Risk infants?

NCT ID NCT07716072

Disease control Sponsor: Nanyang Technological University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This trial tests a 12-week home-based program called SPRINT for infants aged 7-15 months who were born preterm or have a family history of conditions like ADHD, autism, or developmental delay. Parents use an app to guide daily play activities aimed at improving parenting skills and the child's thinking and emotional development. The study compares families who receive the program immediately with those on a waitlist to see if the intervention leads to better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a 12-week home-based, parent-delivered program called SPRINT, delivered via an app with six modules focusing on awareness, bonding, cognition, decoding, emotions, and fun
What this could lead to
If successful, this program could offer a low-cost, scalable way to support early development in at-risk infants and reduce the impact of neurodevelopmental conditions.
What could go wrong
This is an early-stage trial with a small sample size, and the intervention relies on parent engagement, which may vary. Results may not generalize to all families.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

9 to 15 months

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All participants must satisfy the following criteria: * Parent(s) must have access to the internet via a computer, laptop or phone. * Parent (s) with adequate English comprehension skills to participate in the study tasks and provide consent Participants will be included if they meet either of the following criteria: \- Parent(s) with infants who are identified as having increased familial risk of ASD, ADHD, GDD, related neurodevelopmental disorders or premature birth outcomes. Prematurity is defined as being born before 37 weeks. Exclusion Criteria: Participants will be excluded if they meet the following criteria: * Parent(s) and infants with brain injury, severe motor or sensory impairments (e.g., visual or hearing) that would render them unable to participate in the tasks * Parent(s) diagnosed to have impaired intellectual functioning or mental capacity. * Infants with an identified genetic, metabolic, syndromic, or progressive neurological disorder (e.g., epilepsy, Down or Rett Syndrome, Tuberous Sclerosis, Neurofibromatosis, Fragile X Syndrome), including vascular risk factors * Parent (s) with current or pre-existing diagnosed psychological conditions.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Attention deficit/hyperactivity disorder (ADHD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder autism spectrum disorder Emotional Regulation global developmental delay with or without impaired intellectual development learning disability Premature Birth

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Attention deficit/hyperactivity disorder (ADHD) Autism spectrum disorder Global developmental delay Premature birth

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • NTU EMPOWER Centre

    Singapore, 308232, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.